Immunotherapy

Neoadjuvant treatment with immune checkpoint inhibitors for colorectal cancer induced clinical responses that helped delay or prevent surgical resection, results of a study in Journal of the National Comprehensive Cancer Network showed.

Response rates to investigational therapies evaluated in NCI-sponsored phase 1 trials for solid cancers have doubled over the past 2 decades, according to study results published in The Lancet.

Researchers continued to investigate how to help allergy and asthma patients breathe easier, eat better, and live safer and more satisfying lives in 2022. Here are our top 10 stories about these developments this year.

Andrea Schietinger, PhD, will present the 19th AACR-Irving Weinstein Foundation Distinguished Lectureship during the American Association for Cancer Research Annual Meeting, which will be held April 14-19 in Florida.

The success of cancer immunotherapy comes with the risk for severe toxicity, and its efficacy in difficult-to-treat cancers has been accompanied by high rates of disease relapse.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses potentially practice-changing early research on treatments for newly diagnosed multiple myeloma presented at the ASH Annual Meeting and Exposition.

SAN ANTONIO — A symptom pattern model predicted risk for immune-related adverse events among women with early-stage, high-risk breast cancer, according to an analysis of the phase 2 I-SPY2 trial presented at San Antonio Breast Cancer Symposium.

LOUISVILLE, Ky. — In this video, Aikaterini (Katherine) Anagnostou, MD, PhD, FACAAI, shares key takeaways from the International Food Allergy Symposium of the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

2022 has brought many research updates and approvals in lung cancer.

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed an update to the ARROW study.